Context Therapeutics Stock Last Dividend Paid
| CNTX Stock | USD 1.39 0.05 3.47% |
Context Therapeutics fundamentals help investors to digest information that contributes to Context Therapeutics' financial success or failures. It also enables traders to predict the movement of Context Stock. The fundamental analysis module provides a way to measure Context Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Context Therapeutics stock.
Context | Last Dividend Paid |
Context Therapeutics Company Last Dividend Paid Analysis
Context Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Context Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Context Therapeutics is extremely important. It helps to project a fair market value of Context Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Context Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Context Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Context Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Context Dividend Paid And Capex Coverage Ratio
Dividend Paid And Capex Coverage Ratio |
|
Based on the recorded statements, Context Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
Context Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 17.44 M | ||||
| Shares Outstanding | 75 M | ||||
| Shares Owned By Insiders | 1.44 % | ||||
| Shares Owned By Institutions | 76.40 % | ||||
| Number Of Shares Shorted | 802.81 K | ||||
| Price To Book | 1.22 X | ||||
| EBITDA | (25.06 M) | ||||
| Net Income | (23.96 M) | ||||
| Cash And Equivalents | 42.92 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 4.19 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.64 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (21.05 M) | ||||
| Short Ratio | 2.79 X | ||||
| Earnings Per Share | (0.88) X | ||||
| Target Price | 7.7 | ||||
| Beta | 2.25 | ||||
| Market Capitalization | 102 M | ||||
| Total Asset | 16.06 M | ||||
| Retained Earnings | (68.05 M) | ||||
| Working Capital | 11.86 M | ||||
| Net Asset | 16.06 M |
About Context Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Context Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.